You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

~ Buy the RAPIVAB (peramivir) Drug Profile, 2024 PDF Report in the Report Store ~

RAPIVAB Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Rapivab, and what generic alternatives are available?

Rapivab is a drug marketed by Biocryst and is included in one NDA. There are two patents protecting this drug.

This drug has forty-two patent family members in fourteen countries.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the peramivir profile page.

DrugPatentWatch® Generic Entry Outlook for Rapivab

Rapivab was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 12, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for RAPIVAB
International Patents:42
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 142
Clinical Trials: 3
Patent Applications: 1,074
Drug Prices: Drug price information for RAPIVAB
What excipients (inactive ingredients) are in RAPIVAB?RAPIVAB excipients list
DailyMed Link:RAPIVAB at DailyMed
Drug patent expirations by year for RAPIVAB
Drug Prices for RAPIVAB

See drug prices for RAPIVAB

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RAPIVAB
Generic Entry Date for RAPIVAB*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RAPIVAB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of OxfordPhase 2
BioCryst PharmaceuticalsPhase 3
Department of Health and Human ServicesPhase 4

See all RAPIVAB clinical trials

US Patents and Regulatory Information for RAPIVAB

RAPIVAB is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of RAPIVAB is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting RAPIVAB

Antiviral treatments
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER

Antiviral treatments
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER

Antiviral treatments
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER

Antiviral treatments
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS

Antiviral treatments
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for RAPIVAB

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Biocryst Alpivab peramivir EMEA/H/C/004299
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
Withdrawn no no no 2018-04-13
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for RAPIVAB

When does loss-of-exclusivity occur for RAPIVAB?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 06341592
Estimated Expiration: ⤷  Try a Trial

Patent: 07215156
Estimated Expiration: ⤷  Try a Trial

Patent: 13216632
Estimated Expiration: ⤷  Try a Trial

Patent: 16262644
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0621552
Estimated Expiration: ⤷  Try a Trial

Patent: 0707769
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 42260
Estimated Expiration: ⤷  Try a Trial

Patent: 49090
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1420948
Estimated Expiration: ⤷  Try a Trial

Patent: 4784166
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 5483
Estimated Expiration: ⤷  Try a Trial

Patent: 0870263
Estimated Expiration: ⤷  Try a Trial

Patent: 0870430
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 86626
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 12250
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 73202
Estimated Expiration: ⤷  Try a Trial

Patent: 09533428
Estimated Expiration: ⤷  Try a Trial

Patent: 09538822
Estimated Expiration: ⤷  Try a Trial

Patent: 13256527
Estimated Expiration: ⤷  Try a Trial

Patent: 15180695
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 6063
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 08010394
Estimated Expiration: ⤷  Try a Trial

Patent: 08013140
Estimated Expiration: ⤷  Try a Trial

Patent: 20002008
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 0538
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0809012
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1992585
Estimated Expiration: ⤷  Try a Trial

Patent: 2194015
Estimated Expiration: ⤷  Try a Trial

Patent: 2267754
Estimated Expiration: ⤷  Try a Trial

Patent: 2323339
Estimated Expiration: ⤷  Try a Trial

Patent: 2475176
Estimated Expiration: ⤷  Try a Trial

Patent: 080096829
Estimated Expiration: ⤷  Try a Trial

Patent: 140132778
Estimated Expiration: ⤷  Try a Trial

Patent: 160129105
Estimated Expiration: ⤷  Try a Trial

Patent: 180024027
Estimated Expiration: ⤷  Try a Trial

Patent: 190072681
Estimated Expiration: ⤷  Try a Trial

Patent: 200143519
Estimated Expiration: ⤷  Try a Trial

Patent: 210076189
Estimated Expiration: ⤷  Try a Trial

Patent: 210135632
Estimated Expiration: ⤷  Try a Trial

Patent: 230003248
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RAPIVAB around the world.

Country Patent Number Title Estimated Expiration
Mexico 2008013140 TRATAMIENTOS ANTIVIRALES INTRAMUSCULARES. (INTRAMUSCULAR ANTIVIRAL TREATMENTS.) ⤷  Try a Trial
South Korea 102323339 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 0028328 ⤷  Try a Trial
Canada 2642260 TRAITEMENTS ANTIVIRAUX INTRAVEINEUX (INTRAVENOUS ANTIVIRAL TREATMENTS) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.